Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC versus irinotecan + cisplatin as first-line chemotherapy in clear cell ovarian cancer
ISRCTN52615671Phase 3Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- May 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in clear cell ovarian cancer and ovarian cancer comparing Experimental arm: irinotecan + cisplatin with Standard arm: paclitaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started May 2010; status: completed.
02
Drugs
paclitaxelcarboplatinirinotecancisplatin
03
Conditions
clear cell ovarian cancerovarian cancer
Beyond the preview
Go deeper on ISRCTN52615671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52615671.